David Escors-rekin lankidetzan egindako argitalpenak (5)

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. CAR-T Cells for the Treatment of Lung Cancer

    Life, Vol. 12, Núm. 4

  2. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 16

2021

  1. Hyperprogressive disease: Main features and key controversies

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

2019

  1. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy

    EMBO Molecular Medicine, Vol. 11, Núm. 7